Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG101 in patients with gastroparesis
NCT04303195Phase 2Completed
- Sponsor
- Neurogastrx, Inc.
- Start
- Aug 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metopimazine in gastroparesis (4 arms), sponsored by Neurogastrx, Inc. Primary endpoint: Change From Baseline of Nausea Severity Score at 12 weeks. Started Aug 2020; status: completed.
02
Drugs
metopimazine
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT04303195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303195.